Studies of TGEV spike protein gp195 expressed in E. coli and by a TGE-vaccinia virus recombinant.
The gene coding for the surface spike protein gp195 of TGEV has been cloned and expressed in E. coli in the form of fusion proteins. These proteins were isolated and used to immunize laboratory animals. All animals developed antibodies cross-reacting with the TGEV virion but failed to neutralize the virus. The entire gp195 gene was also inserted into vaccinia to generate a TGEV-vaccinia recombinant virus (vTGE) that expressed TGEV gp195. Animals vaccinated with vTGE produced neutralizing antibodies against both TGEV and vaccinia. These results suggest the potential use of the recombinant vTGE as a vaccine against TGEV infection.
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D003001:Cloning, Molecular; D003332:Coronaviridae / Q000235:genetics*; D004274:DNA, Recombinant; D004591:Electrophoresis, Polyacrylamide Gel; D004926:Escherichia coli / Q000235:genetics; D005814:Genes, Viral; D006023:Glycoproteins / Q000235:genetics / Q000276:immunology; D051379:Mice; D008970:Molecular Weight; D009500:Neutralization Tests; D013552:Swine / Q000382:microbiology; D005760:Transmissible gastroenteritis virus / Q000235:genetics* / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics* / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics* / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics*
D000914:Antibodies, Viral; D004274:DNA, Recombinant; D006023:Glycoproteins; D014759:Viral Envelope Proteins; D014765:Viral Vaccines